CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
Study Number: NSABP C-14
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Bloomington, Canton, Galesburg, Ottawa, Pekin, Peoria, Peru, and Washington clinics
- Navigator Carrie, 309-243-3621 firstname.lastname@example.org
- Beth, 309-243-3617 email@example.com